Riad Salem, MD, MBA - Making Headway Towards Better Outcomes in Intermediate- to Advanced-Stage Hepatocellular Carcinoma: A Multidisciplinary Tumor Board on Implementing Novel Locoregional and Systemi

Go online to PeerView.com/NUC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Are you prepared to keep up with changes to the treatment landscape of hepatocellular carcinoma (HCC) as the choice of regimens for patients with intermediate- to advanced-stage disease continues to expand and innovative locoregional and multimodal strategies move closer to entering mainstream clinical practice? With several available treatment modalities, HCC requires a multidisciplinary approach that is based on both disease stage and a variety of patient- and treatment-specific factors. Participate in this PeerView activity for an in-depth examination of how interventional radiologists can collaborate with the HCC management team to offer the best possible care for their patients! Upon completion of this activity, participants should be better able to: Evaluate the current and emerging therapeutic roles of and key clinical evidence on novel systemic therapy options, including multikinase inhibitors, anti-angiogenic agents, immune checkpoint inhibitors, and combinations, for patients with intermediate- to advanced-stage HCC; Recommend clinical trials assessing innovative strategies, including tumor treating fields, Y-90 glass and resin microspheres, and combinations of locoregional and systemic therapies, to patients with HCC across the disease spectrum; and In collaboration with multidisciplinary colleagues, develop evidence-based management plans that incorporate novel therapeutic approaches, patient-specific factors such as underlying liver disease severity and biomarker status, and expert recommendations on timely transitions from locoregional to systemic therapy for patients with intermediate- and advanced-stage HCC.